BeyondSpring, which is developing a cancer therapy to combat the loss of white blood cells, raised $3 million by offering 0.17 million shares at $20, the low end of the range of $20 to $22. BeyondSpring plans to list on the Nasdaq under the symbol BYSI. Rodman & Renshaw acted as a lead manager on the deal.
